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Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) models are important vehicles for studying the effect of
infectious elements such as Pertussis toxin (PTx) on disease processes related to acute demyelinating encephalomyelitis
(ADEM) or multiple sclerosis (MS). PTx has pleotropic effects on the immune system. This study was designed to investigate
the effects of PTx administered intracerebroventricularly (icv) in preventing downstream immune cell infiltration and
demyelination of the spinal cord.
Methods and Findings: EAE was induced in C57BL/6 mice with MOG35–55. PTx icv at seven days post MOG immunization
resulted in mitigation of clinical motor symptoms, minimal T cell infiltration, and the marked absence of axonal loss and
demyelination of the spinal cord. Integrity of the blood brain barrier was compromised in the brain whereas spinal cord BBB
integrity remained intact. PTx icv markedly increased microglia numbers in the brain preventing their migration to the
spinal cord. An in vitro transwell study demonstrated that PTx inhibited migration of microglia.
Conclusion: Centrally administered PTx abrogated migration of microglia in EAE mice, limiting the inflammatory cytokine
milieu to the brain and prevented dissemination of demyelination. The effects of PTx icv warrants further investigation and
provides an attractive template for further study regarding the pleotropic effects of infectious elements such as PTx in the
pathogenesis of autoimmune disorders.
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is the
primary animal model of multiple sclerosis (MS). The inflamma-
tory reaction in the central nervous system (CNS) is driven by
induction of auto-reactive immune cells which survey and
penetrate the brain [1,2]. The vulnerability of spinal cord and
the progression of deficits from caudal to rostral in EAE has been
attributed to the increased permeability of the blood brain barrier
(BBB) and susceptibility of the distal motor and sensory fibers to
macrophage/microglia mediated demyelination [3,4,5].
There is growing interest regarding the role of pertussis toxin (PTx)
on autoimmunity and disease processes such as acute demyelinating
encephalomyelitis (ADEM) or MS. PTx is an immune adjuvant
utilized to effectively promote inflammation and compromise the
BBB facilitating leukocyte infiltration/migration into the CNS [6,7].
Microglial activation and migration is essential for the develop-
ment of demyelination and clinical symptoms in EAE [8]. There is
considerable evidence of a primary role of microglia in MS as well,
particularly secondary progressive MS [9,10]. Activation of
macrophage/microglia dominates the pathologic picture early in
the course of disease in EAE, before the onset of clinical symptoms
and to a much greater magnitude than T cells [11,12]. Microglia act
as antigen presenting cells (APC) and are responsible for the
subsequent activation and infiltration of T cells [8,13]. Further-
more, they strip and phagocytize myelin stimulating further the
induction of auto-reactive CD4 cells [14,15]. Persistent activation of
microglia plays an important role in the development of local
inflammatory injury, and the timing of this activation is critical to
the progression of autoimmune disease such as EAE.
A time course study in EAE found evidence of two step process
mediating T cell and macrophage infiltration [11]. Initially T cells
and macrophages access the CNS through the ventricular and
meningeal CSF channels. Although there is considerable accu-
mulation of macrophage/microglia and to a lesser extent T cells in
the subpial and subependymal regions of the brain, the vasculature
appears to be uncompromised. Prior to day 7, there is no evidence
of spinal involvement except in the distal meninges of the cord,
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presumably where the BBB is limited. However, subsequent
vascular infiltration and associated demyelination, mediated by
macrophage/microglia localize to the distal motor and sensory
fibers of the spinal cord [11]. There is considerable evidence that
PTx prevents the migration of macrophage/microglia localizing
the inflammatory milieu [16]. We hypothesize that confining
inflammatory infiltration to the brain through the intraventricular
administration of PTx would limit downstream infiltration of the
spinal cord. We demonstrate disruption of the BBB and brain
parenchymal infiltration of macrophage and to a lesser degree T
cells on day 7 in the MOG33–55 induced EAE mice after PTx icv.
This results in the attenuation of the spinal cord motor symptoms
with minimal evidence of infiltration or demyelination. Cytokine
concentration and the inflammatory milieu are localized to the
brain. There is considerable interest in the basis of pathologic
targeting in EAE as well as in MS and its variants [17,18].
Manipulating pathogen administration in EAE may provide us
with clues regarding the role of pathogens in the development of
disease as well as in the containment of the monophasic forms.
Materials and Methods
EAE induction and treatment
All experimental procedures were approved by the Institutional
Animal Care and Use Committee of the Barrow Neurological
Institute (Protocol number 309) and performed according to the
Revised Guide for the Care and Use of Laboratory Animals. The
animals were kept in groups on a 12:12 h light/dark cycle with
food and water ad libitum.
EAE was induced in female C57BL/6 mice (6–8 weeks old,
Taconic Laboratory, New York, USA) by subcutaneous injection
with 200 mg myelin oligodendrocyte glycoprotein (MOG35–55;
M-E-V-G-W-Y-R-S-P-F-S-R-V-V-H-L-Y-R-N-G-K, Bio-synthesis
Inc. Lewisville, TX), dissolved in an emulsion of 50 ml of complete
Freund’s adjuvant containing 0.5 mg of heat killed Mycobacterium
tuberculosis (CFA, Difco Laboratories, Detroit, MI) and 50 ml of
phosphate buffered saline (PBS). On the day of immunization (day
0) and 48 h later (day 2), PTx (List Biological laboratories Inc.)
200 ng in PBS was injected into the mouse tail vein [19].
Neurological functional tests were performed by an examiner
blinded to the treatment status of each animal. Functional data were
collected on 7 mouse groups (n= 12/group), 3 PTx icv treatment
groups (EAE+ PTx icv 1000 ng, 400 ng, and 200 ng), 2 EAE
groups (EAE and EAE+ normal saline (NS) icv) and 2 non-EAE
control groups (normal +1000 ng PTX icv and CFA +1000 ng
PTX icv). Neurological assessments were reported using a five-point
standardized rating scale to evaluate motor deficit: 0 no deficit; 1 tail
paralysis; 2 unilateral hind limb weakness; 3 incomplete bilateral
hind limb paralysis and/or partial forelimb weakness; 4 complete
hind limb paralysis and partial forelimb weakness; 5 moribund state
Figure 1. EAE +PTx icv mice developed an attenuated and delayed course of EAE. Clinical scores were evaluated daily in EAE +PTx icv and
control mice and were plotted as the mean 6 S.D (n = 12/group). Maximum clinical scores as well as scores on day 14 and 23 evidence marked
attenuation of disease severity after PTx icv (P,0.01). A dose response to PTx icv is demonstrated as well. Mice receiving lower doses of PTx icv
(400 ng and 200 ng) continued to manifest a dose dependent benefit compared to the EAE controls (P,0.05).
doi:10.1371/journal.pone.0012400.g001
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or death [20]. Scores were measured daily for 23 days. The onset of
disease was calculated by determining the total number of days from
MOG35–55 immunization to the onset of symptoms in individual
animals. Maximal motor scores and motor scores at day 14 and 21
were compared as were onset of disease.
Stereotactic intracerebroventricular injection
Mice were anaesthetized by injection of a ketamine/xylamine
cocktail on day 7 after MOG35–55 immunization and mounted in a
stereotactic device. A fine hole was drilled through the skull giving
access to the surface of the brain 0.7 mm caudal to bregma and
1.0 mm lateral to the sagittal suture. A guarded, 27-gauge 0.5-in
needle was stereotactically inserted, targeting the lateral ventricle
(3.5 mm depth). A 10.0-ml Hamilton 1700 series gastight syringe was
used to inject 2 ml of normal saline, or PTx (500 mg/ml dissolved in
normal saline) into the lateral ventricle over a five-minute period.
Immunohistochemistry
Mice were euthanized at day 7 14 or day 23 post immunization.
Terminally anesthetized mice were intracardiacally perfused with
saline followed by 4% paraformaldehyde. The spinal cord and
brain were embedded in paraffin and cut into serial 6-mm thick
coronal slides. Histological evaluation was performed by staining
with hematoxylin and eosin (H&E), Luxol fast blue/periodic acid
Schiff agent (LFB/PAS), and Bielschowsky silver impregnation to
assess inflammation, demyelination, and axonal pathology,
respectively.
Histological scores assessing the degree of inflammation,
demyelination, and axonal loss in the spinal cord were evaluated
using a semi-quantitative system. In brief, the degree of
inflammation was assessed by counting the number of cellular
infiltrates in the spinal cord. Digital images were collected using an
Axoplan microscope (Zeiss, Thornwood, NY) under bright field
setting using a 40X objective. Severity of inflammatory cell
infiltration on H&E staining was scored using the following scale as
described [21]: 0, no inflammation; 1, cellular infiltrates only
around blood vessel and meninges; 2, mild cellular infiltrates in
parenchyma (1–10/section); 3, moderate cellular infiltrates in
parenchyma (11–100/section); and 4, serious cellular infiltrates in
parenchyma (.100/section).
Serial sections of paraformaldehyde-fixed spinal cord were
stained with Luxol fast blue for myelin and were assessed in a
blinded fashion for demyelination using the following scale [22]: 0,
normal white matter; 1, rare foci; 2, a few areas of demyelination;
3, confluent perivascular or subpial demyelination; 4, massive
perivascular and subpial demyelination involving one half of the
spinal cord with presence of cellular infiltrates in the CNS
parenchyma; and 5, extensive perivascular and subpial demyelin-
ation involving the whole cord section with presence of cellular
infiltrates in the CNS parenchyma. Axonal loss was assessed using
the following scale [23]: 0, no axonal loss; 1, a few foci of
superficial axonal loss which involves less than 25% of the lateral
columns; 2, foci of deep axonal loss and that encompasses over
25% of the lateral columns; and 3, diffuse and widespread axonal
loss. At least six serial sections of each spinal cord from each mouse
were scored and statistically analyzed by ANOVA. Data were
presented as Mean 6 Standard deviation (SD).
Immunohistochemistry was performed with rabbit polyclonal
antibodies against IL-6 (1:2000, #ab6672, Abcam Inc; Cam-
bridge, MA), and TGF-b (1:3000, #ab66043, Abcam Inc;
Cambridge, MA) to identify crucial pro-inflammatory cytokines;
and against ionized calcium binding adaptor molecule 1 (Iba-1,
1:2500, Wako Chemicals Inc. LA) for microglia [16] and glia
fibrillary acidic protein (GFAP, 1:400, Millipore Corporation,
Billerica, MA) for astrocytes. Sections of brain and spinal cord
stained with anti-Iba1 allowed quantification of microglia and
assessment of its morphology. We performed a morphological
analysis of the changes observed and quantified the microglia in
sections of cerebral cortex and spinal cord [24].
Figure 2. T cell proliferation responses to the Ag (MOG35–55 peptide) were assessed in triplicate wells for each experiment. It showed
a significant difference in PTx+ EAE and EAE versus control (* p,0.01). But there was no difference between PTx+ EAE and EAE mice. Results are
expressed as Dcpm (mean cpm stimulated cultures – mean cpm unstimulated cultures). N = 6/group.
doi:10.1371/journal.pone.0012400.g002
PTx Prevents Dissemination
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12400
Th17 cells were identified by double immunostaining for
CD4 (1:1600, Chemicon, Temecula, CA), and IL-17 (1:3000,
rabbit mAb, #ab40663, Abcam Inc., Cambridge, MA)
with two fluorescent conjugated secondary antibodies (FITC
conjugated and Texas Red conjugated). Immunolabeling
was detected by applying the peroxidase-antiperoxidase pro-
cedure with 3, 39-diaminobenzidine (DAB) as cosubstrate
[25]. Negative control slides received identical preparations
for immunostaining, except that primary antibodies were
omitted.
Western blot protein analysis
Aliquots of equal amount of proteins were loaded onto a 10%
SDS-polyacrylamide gel. After gel electrophoresis, blots were
subsequently probed with primary antibodies (anti- IL-6, 1:1000
#ab6672, anti- IL-17, 1:3000 #ab40663, anti-TGF-b 1:1000
#ab66043 Abcam Inc; Cambridge, MA). For detection, horse-
radish peroxidase-conjugated secondary anti-rabbit antibody was
used (1:10,000, #7074, Cell signaling technology; Danvers, MA),
followed by enhanced chemiluminescence development (ECL kit,
#34077, Thermo Scientific Pierce, Rockford IL).
Figure 3. Flow cytometry analysis of mononuclear cells from the spleen on day 14. PTx icv does not alter the peripheral lymphocyte
subpopulation in acute EAE. Dot plots of flow cytometry results generated after gating on lymphocytes (by forward and versus side scatter) are
shown for T (CD3+, CD4+, CD8+, CD4+/CD25+ and B (CD32/CD19+) cells. WT=wild type group. Absolute numbers of lymphocyte subpopulation,
macrophage/microglia cells are shown in the following table. n = 6/group. * p,0.05 compared with WT, * * p,0.01 compared with WT.
doi:10.1371/journal.pone.0012400.g003
PTx Prevents Dissemination
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Normalization of results was ensured by running parallel
Western blots with b-actin antibody (1:25,000 #ab49900, Abcam
Inc; Cambridge, MA). The optical density was quantified using an
image densitometer (Model GS-670, BioRad, Hercules, CA). The
data are presented as a percentage of target protein relative to
b-actin. A value of p,0.05 is considered significant.
BBB studies
Qualitative (immunohistochemistry) and quantitative (Western
blot) analyses of exogenous rabbit IgG penetration across the BBB
into the CNS were used to evaluate the extent of regional breakdown
of the BBB in EAE and EAE+ PTx icv mice [20]. Normal and PTx
icv (without EAE) were used as controls. Mice were injected
intraperitoneally (i.p.) with 100 mg purified rabbit IgG (Ir-Rb-Gf,
Innovative research, Novi, MI, USA) on day 7 (four hours after PTx
icv in the EAE+ PTx icv group) or day 14. Animals were euthanized
18–19 hours after the injection. For immunohistochemistry, paraffin
embedded sections were probed directly with biotinylated anti-rabbit
IgG (1:100; Vector laboratories, Brulingame, CA). For Western blot,
the horseradish peroxidase-labeled anti-rabbit antibody (1:5000, Cell
Signaling Technology, Davers, MA) was used.
T cell proliferation assays
Animals were sacrificed on day 14. Mononuclear cells were
isolated from the spleen and were suspended in culture medium
containing DMEM supplemented with 1% penicillin-streptomycin
and 10% (v/v) FBS (Invitrogen Life Technologies). Mononuclear
cells were then seeded onto 96-well plates at a concentration of
46105 cells/well. Ten microliters of MOG35–55 peptide (10 mg/
ml), PLP139–151 peptide (10 mg/ml), or Con A (5 mg/ml; Sigma-
Aldrich) were then added in triplicate into the wells. After 3 days of
incubation, the cells were pulsed for 18 h with 10-ml aliquots
containing 1 mCi of [methyl-3H] thymidine (42 Ci/mmol; Amer-
sham Biosciences). Cells were harvested onto glass fiber filters, and
the thymidine incorporation was measured. The results were
expressed as Dcpm (DCPM) (mean cpm stimulated cultures –
mean cpm unstimulated cultures) [19].
Flow cytometry analysis
To evaluate the frequency of CD4+, CD8+, CD4+/CD25+,
CD32/CD19+, CD45+/CD11b+ cells, spleen mononuclear cell
culture was prepared from each group on day 14 (the peak of auto-
immune response). Single cell suspensions (26106 cells/5 ml BD
tube) were incubated with combinations of fluorescent antibodies,
for 30 min at 4uC: CD3 (17A2), CD19 (1D3), CD4 (GK 1.5), CD8
(53–6.7), CD25 PC61.5), CD11b (M1/70), and CD45 (RA3-6B2).
The indicated antibodies were fluorescently tagged with either
FITC, PE, allophycocyanin, PE-Cy5, PE-Cy7 or APC-Cy7. All
purchased from BD Pharmingen. After incubation, each suspen-
sion was washed twice (400 g, 5 min, 4uC) with PBS containing
2% bovine serum albumin (BSA) and was resuspended in PBS
with 0.5% of paraformaldehyde. Appropriate isotype controls
were included. All samples were analyzed on Accuri C6 Flow
Cytometer (Accuri Cytometers Inc, USA). Data were analyzed on
CFlow Plus software. The number of mononuclear cells per mouse
spleen was counted on hemocytometer and the absolute number of
a cell subset was calculated based on the percentage of cells stained
for the appropriate markers [19].
Cytokine quantification by Enzyme-Linked
Immunosorbent Assay (ELISA)
To assess cytokine expression, spleen mononuclear cells were
prepared as described above. Suspensions were incubated in
RPMI-1640 medium at 37uC for 2 days (26106 cells/well) with or
without antigens (MOG35–55 10 mg/ml or Con A 5 mg/ml,
Sigma,USA). Supernatants were collected and aliquoted in 96-well
plate precoated with antibodies to Interferon c (IFN- c), Tumor
Necrosis Factor a (TNF-a), Interleukin-2 (IL-2), Interleukin-4
(IL-4), Interleukin-6 (IL-6) and Interleukin-10 (IL-10) (ELISA
MaxTM Set Deluxe, BioLegend Inc. San Diego, CA). Optical
density was measured at 450 nm on Model 680 Microplate Reader
(Bio-Rad Laboratories, Corston,UK). The optical density was
quantified by GraphPad Prism 4 (GraphPad Software,Inc) using
the standard curve provided by the manufacturer [19].
Primary microglia cell culture
Cortical tissue was harvested from 0 or 1-day-old C57/BL6
mouse pups (Taconic, Hudson, NY). Meninges and visible
vasculature were removed under a dissecting microscope. Cortical
tissue was digested in the DMEM/F12 media (Invitrogen
Corporation, CA) containing 0.25% trypsin and EDTA (1 mM)
at 37uC for 15 minutes. The digested tissue was resuspended in
20 ml media containing DMEM/F12 supplemented with 15%
heat inactivated fetal bovine serum, 5% Horse serum (Sigma, St.
Louis, MO) and 1% Penicillin-Streptomycin and filtered through a
70-mm nylon mesh (BD Biosciences, San Jose, CA). The cells were
washed and seeded in a 75 cm2 flask in fresh culture medium (3–
4 Pups/per flask). The purity of the microglia cultures was assessed
by double-immunostaining with microglial special markers anti
Ionized calcium binding adaptor molecule 1 (Iba-1, 1:2500, Wako
Chemicals Inc. LA) and glia fibrillary acidic protein (GFAP, 1:400,
Millipore Corporation, Billerica, MA). The purity of this primary
microglia cell culture is about 90–95% [26].
Microglia migration assay
The migration of microglia in vitro was determined by using
Transwell (pore size 8-mm, Corning, VWR, San Dimas, CA). Cell-
free DMEM/F-12 media (0.8 ml) with or without IFN-c (20 ng/
ml, BD Biosciences, San Jose, CA) was placed in the lower
chamber. Microglia suspension (0.1 ml, 56104 cell/per well) was
placed in upper chamber and incubated with or without PTx
(100 ng/ml, Campbell, CA) for 24 hours at 37uC. The inserts
were then removed and the upper surface was carefully cleansed
with cotton pads. Cells on the lower surface were air dried and
stained for microglia. Microglial migration was quantified and
compared among the groups by counting the number of cells that
migrated through the membrane to the lower chamber. Five
random fields at 40X fields were counted for each condition under
Table 1. Splenocytes from EAE and EAE+ PTx mice expressed
elevated levels of TNF-a, IFN-c, IL-2, IL-6, and IL-4 compared to
WT controls.
pg/ml WT EAE EAE+PTx
TNF-a 3.060.9 46.762.0* 49.361.9*
IFN-c 9.968.9 2385.96556.9* 2636.26186.9*
IL-2 5.460.6 105.9626.0* 138.2623.1*
IL-6 14.163.8 1144.06211.5* 1047.06186.1*
IL-4 1.360.4 170.9662.5* 144.3611.3*
There was no significant difference in cytokine production in EAE and EAE+ PTx.
* P,0.001, compared with WT. Abbreviation: WT: wild type, EAE: Experimental
autoimmune encephalomyelitis model group, EAE+ PTx: EAE mice with cerebral
ventricle injection of Pertussis toxin (PTx).
doi:10.1371/journal.pone.0012400.t001
PTx Prevents Dissemination
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a phase contrast microscope. Each experiment was repeated three
times. Results were shown as the cells counted per 40X field [27].
Statistical analysis
Data were analyzed with SPSS version 10 for windows. The two-
way analysis of variance was applied to determine the significance of
the difference among the experimental groups. Kruskal-Wallis
nonparametric analysis was used for data presented as percentage.
The Mann-Whitney U test was used when Kruskal-Wallis showed
significance among groups. P,0.05 was considered significant.
Results
1. PTx icv prevents against dissemination of motor
deficits in EAE and has a dose effect
PTx icv (1000 ng) delayed the onset of motor symptoms
(11.660.64 versus 8.560.75, p,0.05) and decreased the severity
of motor impairment (maximal clinical score 0.3560.07 vs.
3.2560.37, p,0.01) (Fig. 1). We evaluated whether there was a
dose effect associated with administration of PTx icv (200 ng,
400 ng, and 1000 ng). There was a significant dose effect. The
1000 ng group provided a significantly greater therapeutic
response than the 400 ng, and the 400 ng greater than the
200 ng (p,0.05) which also provided a significant therapeutic
response relative to EAE (p,0.05) (Fig. 1).
To control for potential effects of icv administration, EAE mice
were treated with same volume of normal saline icv (EAE +NS
icv). Motor deficits were unchanged compared to EAE alone
(Fig. 1). To determine whether the effects of the spinal cord lesion
could be alleviated following symptom onset, PTx icv was
administered immediately after the onset of measurable motor
deficits (clinical score.0.5; day 9+ post MOG35–55 inoculation).
The delayed administration did not alter the clinical course of
EAE (n= 6; data not shown).
2. The variation in clinical disease is not due to
differences in auto-reactive T cell priming
To investigate whether an enhanced expansion of auto-reactive
T cells could be responsible for the observed clinical differences in
EAE versus EAE +PTX icv, T cells were re-challenged with
MOG35–55 in vitro. No differences were observed between EAE
and EAE +PTX icv regarding the capacity of T cells to proliferate
in response to recall antigen (Fig. 2). Furthermore there was no
difference in T cell subpopulations (CD4+, CD8+, CD4+/CD25+),
B cell (CD32/CD19+), and macrophage/microglia (CD45+/CD
11b+) (Fig. 3). Nor is there a pattern shift in Th1/Th2 between the
two groups (Table 1).
3. PTx icv attenuates spinal cord leukocyte infiltration
and demyelination in EAE
On day 14 and 23, H&E staining in the cross-sectional of the
spinal cord of EAE mice showed widespread infiltration of
inflammatory cells in the spinal cord (Fig. 4D–F). In contrast,
EAE+PTx icv mice exhibited markedly decreased infiltration of
inflammatory cells in the spinal cord on day 14 and 23. (Fig. 4A–
C, Table 2).
To determine the degree of demyelination, we stained sections
of spinal cord with Luxol fast blue and observed widespread
demyelination zones in the white matter of the spinal cord of
EAE mice on day 14 and 23 (Fig. 4H). In contrast, on day 14 and
23, mice that received PTx icv had minimal evidence of
demyelination indicated by a markedly attenuated course of
disease (Fig. 4G, Table 2). Marked axonal loss characterizes the
MOG35–55 model of EAE, and this is evident in the spinal
sections of the EAE mice assessed with Bielschowsky silver
impregnation. Attenuation of axonal injury is evidenced in EAE
+PTx icv mice (Table 2).
4. PTx icv increases BBB permeability in EAE
We determined BBB integrity by localizing rabbit IgG in the
CNS in EAE and EAE +PTx icv before (day 7) and during
the peak (day 14) of symptomatic disease. On day 7, rabbit IgG
immunoreactivity was observed in the brains of EAE +PTx icv
but not in EAE mice (Fig. 5, 6). In the spinal cord no
immunoreactivity was observed in either group. On day 14,
EAE mice demonstrated immunoreactivity diffusely throughout
the parenchyma of the spinal cord with minimal evidence of
reactivity in the brain. EAE +PTx icv mice showed rabbit
IgG immunoreactivity in the brain, but not in the spinal cord
(Fig. 5, 6).
To control for potential effects of PTx on BBB integrity,
separate from its exacerbation of EAE related inflammation, mice
were treated with 1000 ng PTx icv but were not exposed to
MOG35–55. In contrast to EAE +PTx icv mice (Fig. 5, 6), mice that
received only PTx icv exhibited no accumulation of rabbit IgG in
the brain or the spinal cord (data not shown). Thus, the BBB
Figure 4. Attenuation of the progression of inflammation and tissue injury in the CNS of mice that received PTx icv. Pathological
examination of spinal cord sections from EAE +PTx icv and EAE mice were performed at 7, 14, and 23 days post EAE induction to evaluate CNS
inflammation, demyelination and axonal damage. In EAE +PTx icv mice, the number of immune-cell infiltrates (H&E staining, Fig. 4A–C) and
demyelination (Luxol fast blue staining, Fig. 4G) were both significantly reduced at day 14 and 23 post EAE induction. Representative day 14 images
of H&E staining (A–F) and LFB/PAS staining (G, H). B and C were inserts in A; E and F were inserts in D. Original magnification640 in A, D, G and H;
6200 in B, C, E, F, and inserts in G and H.
doi:10.1371/journal.pone.0012400.g004
Table 2. Histopathological analyses of inflammatory
parameters, demyelination and axonal damage in the spinal
cord of C57BL/6 mice at 7, 14, and 23 days after MOG35–55 EAE
induction.
EAE EAE+PTx icv P value
Inflammation (H&E)
day 7 0.2560.27 0.0860.20 0.260
day14 3.3360.75 1.3360.75 0.001*
day 23 3.4260.58 1.3360.68 ,0.001*
Demyelination (Fast blue)
day 7 0.2560.27 0.0860.20 0.260
day 14 3.6660.98 0.8360.98 0.001*
day 23 3.7560.93 1.1660.98 0.001*
Axonal loss (silver staining)
day 7 0.8360.20 0.0460.10 0.664
day 14 2.4260.86 0.6660.51 0.002*
day 23 2.5860.97 0.5860.49 0.001*
Data were presented as Mean 6 SD.
doi:10.1371/journal.pone.0012400.t002
PTx Prevents Dissemination
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Figure 5. Rabbit immunoglobulin G (IgG) penetration into the frontal lobe parenchyma and thoracolumbar spinal cord in control,
EAE, and EAE +PTx icv (n=7/group). Normal +IgG: age-controlled normal mice without EAE receiving a single i.p. injection of rabbit IgG (100 mg/
mouse). 7 days EAE: EAE mice on day 7 post immunization; no penetration of rabbit IgG observed in the brain or spinal cord. 14 days EAE: EAE mice on
day 14; marked penetration of rabbit IgG noted in both brain and spinal cord. 7 days EAE +PTx: EAE +PTx icv mice on day 7 post immunization; marked
penetration of the brain, but no penetration of the spinal cord. 14 days EAE +PTx: EAE +PTx icvmice on day 14 post immunization, continued evidence of
brain penetration, no penetration of the spinal cord. Note the dramatic opening of the BBB on Days 7 in EAE +PTx icv group relative to EAE on day 7.
doi:10.1371/journal.pone.0012400.g005
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breakdown described above was caused by the effect of PTx icv in
the context of EAE.
5. PTx icv preferentially induces the development of
myelin-reactive Th-17 cells in the brain
T helper cell lineage development depends on local cytokine
milieus and specific immune factors. Emerging evidence supports
the pathonogmonic role of Th-17 cells in EAE and the role of PTx
in the induction of Th-17 [28]. For the Th-17 cells, TGF-b and
IL-6 drive the initial lineage commitment. We quantified the Th-
17 cell concentration in our model after PTx icv was administered.
In the spinal cord, the presence of IL-17 CD4 cells was rare and
limited to the meninges in the EAE +PTx icv mice (Fig. 7A–C),
whereas a considerable number of Th-17 cells were identified in
the spinal parenchyma of the EAE mice (Fig. 7D–F). The protein
levels of IL-17, IL6 and TGF-b (Fig. 7G–I) were significantly
Figure 6. The western blot depicts measures of rabbit IgG. Lane 1: purified rabbit Ig G as the positive control; lane 2–7 correlates the plotted
graph below. Statistical evaluation of optic density (OD) normalized to b-actin was obtained for each group. Mean 6 SD are depicted (n = 7 per
group). *P,0.01, compared with normal control; **P,0.01, compared with normal control group and EAE.
doi:10.1371/journal.pone.0012400.g006
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elevated in the spinal cord of the EAE relative to the EAE +PTx
icv mice (p,0.05), correlating the spinal cord pathology in EAE
mice.
In the brain, the EAE +PTX icv mice exhibited infiltrating
leucocytes which stained positive for CD 4 and IL-17. The
majority of these colocalized cells were in the periventricular white
matter, confirming the infiltration of proinflammatory of Th-17
cells induced by PTx icv. Whereas, in the EAE alone mice, the
presence of Th-17 cells in the brain was limited to the meninges.
The protein level of IL-17, IL-6, and TGF-b were significantly
elevated in the brain of EAE+ PTx icv mice, relative to the
controls and the EAE alone mice (Fig. 8) (p,0.05). In normal
control and CFA+ PTx icv groups, no IL-17+ cells were detected
in brain.
Figure 7. Inflammatory cytokines and cells in the spinal cord of EAE and EAE +PTx icv mice (n=6/group). IL-17+/CD4+ cells were
detected in the meninges of the spinal cord in the EAE +PTx icv mice (A–C), whereas these cells were diffusely identified in the spinal parenchyma in
the EAE mice (D–F). Original magnification6400. The western blot depicts measures of IL-17 (G), IL-6 (H) and TGF-b (I). In the spinal cord, elevated
levels of all three were identified in the EAE mice relative to the EAE +PTx icv mice. Statistical evaluation of optic density (OD) normalized to b-actin
was obtained. Mean 6 SD are depicted (n = 6 per group). *P,0.05, compared with normal control group; #P,0.05, compared with EAE group.
doi:10.1371/journal.pone.0012400.g007
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6. PTx icv retains macrophage/microglia and to a lesser
degree T cell infiltration to the brain preventing
dissemination to the spinal cord
The most salient finding of PTx icv on day 7 post immunization
was the parenchymal infiltration of macrophage/microphage
(Iba1), and to a lesser magnitude T cell (CD4), in the brain
(Fig. 9). In the brain of EAE+ PTx icv mice, anti-Iba1 antibody
reacted strongly with amoeboid-shaped cells, corresponding to
activated microglia on day 7. Wild type controls manifest ramified
or resting microglia; whereas EAE mice manifest intermediate
responsiveness and ramification (Fig. 9-C, D, F). In contrast, the
spinal cord of EAE mice showed amoeboid-shaped cells that
stained strongly with anti-Iba1 antibody, corresponding to
activated microglia (Fig. 9-A, B, E). To further determine the
effect of PTx on microglia migration, we utilized the Transwell to
assess in vitro migration. PTx significantly inhibited the migration
of microglia with and without IFN-c stimulation (Fig. 10).
Discussion
Several studies in different animal models have demonstrated
that macrophage/microglia activation and infiltration are essential
for the development of clinical EAE [29,30,31]. This has been
verified in numerous studies which traced the therapeutic effects to
the disruption of macrophage/microglia function [15,32,33].
Macrophage cells differentiate into both microglia-like and
dendritic-like cells in the CNS during EAE [34]. They function
as antigen presentation cells to the encephalitogenic T cells
[13,35]. Macrophage/microglia strip off myelin from axons and
through receptor mediated pathways phagocytize myelin [36,37].
Activated microglia through the production of a proinflammatory
milieu disrupt the blood-brain barrier (BBB) integrity, attract and
activate of T cells and monocytes which augments the destruction
of myelin [33].
Time course studies on MOG induced EAE indicate that
immune cell initiation of EAE occurs in stages and inflammatory
interactions among resident microglia, invading T lymphocytes
and neuronal elements occur prior to the onset clinical EAE in
lawful temporal and spatial relationship to one another [11]. Their
emergence before the onset of EAE clinical symptoms and their
localization in the inflammatory lesions indicate that they play a
major role in the initiation and progression of EAE [38].
The earliest stage of EAE, appears to occur on and prior to day
7 (prior to the onset of clinical features), is characterized by a
Figure 8. The western blot depicts measures of IL17 (A), IL6 (B) and TGF-b (C) in the brain of EAE +PTx icv compared with in EAE
alone mice as well as controls. Statistical evaluation of optic density (OD) normalized to b-actin was obtained. Mean +/2 SD are depicted (n = 6
per group). *P,0.05, compared with normal control group; #P,0.05, compared with EAE group.
doi:10.1371/journal.pone.0012400.g008
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marked accumulation of activated macrophage/microglia in the
sub-ependymal (periventricular) and subpial regions of the brain
parenchyma. The presence of limited infiltration in these regions
and the sparing of vascular structures indicates this stage involves
modest infiltration primarily through CSF venues. Furthermore, T
cell presence considered primary in the development of EAE is
modest compared with the accumulation of macrophage/microg-
lia suggesting a greater T cell stimulatory role of microglia possibly
involving their APC potential [11]. This is supported by evidence
that subsequent stages (.=10–14 d) are distinguished by more
pronounced infiltration of T cells which define inflammatory foci
as well as the onset of motor symptoms [11,38].
The findings described above in our studies and others indicate
that the initial APC and T-cell recruitment in EAE occurs at the
meninges and choroid plexus rather than at the vasculature and
suggested that the inflammatory responses in the form of
microglial activation at distal levels of afflicted pathways might
be involved in subsequent macrophage and T cell transit across
the vasculature in the spinal cord [11]. After PTx icv however,
rapid disruption of the BBB in the brain was detected indicating
macrophage and T cell transit across vasculature. PTx icv early in
the course of disease prevented downstream disruption of the BBB,
whereas later administration (.=10–14 days) did not alter the
course of disease in the spinal cord. This indicates a time
dependent cascade mechanism regarding prevention of down-
stream vasculature compromise.
PTx has a multitude of effects on the immune system. In EAE, the
animal model for MS, it has been considered an immune adjuvant
responsible for a more severe course of disease and the induction of
disease in animals not previously susceptible [39]. PTx degrades of
integrity of the BBB, activates microglia, and induces the infiltration
of effector T cells and macrophages creating a proinflammatory
milieu of cytokines [28,39,40]. However, there is considerable
evidence that PTx through its direct effect on T cells and antigen
presenting cells (APC) inhibits the migration of immune cells
preventing dissemination of inflammation [41].
Figure 9. Anti-Iba1 immunostaining of spinal cord and brain of WT, EAE and EAE + PTx icv mice. Brain and spinal cord sections were
immuno-stained at 7 days post MOG immunization with the anti-Iba1 antibody. A: Low-magnification image of spinal cord section (Scale
bar = 200 mm). The anti-Iba1 antibody reacted strongly with amoeboid-shaped cells, corresponding to activated microglia in the spinal cord of EAE
mice. This was significantly less prominent in the EAE+ PTx icv mice. In WT controls, the antibody also effectively, but rather weakly, recognized
ramified or resting microglia; these cells have small bodies and finely branched processes. B: High-magnification image of the spinal cord sections
(Scale bar = 50 mm). C: Low-magnification image of cerebral cortex (Scale bar = 200 mm). The anti-Iba1 antibody reacted strongly with amoeboid-
shaped cells, corresponding to activated microglia in the brain of EAE+ PTx icv mice. WT controls manifest ramified or resting microglia; whereas EAE
mice manifest an intermediate stage. D: High-magnification image of the brain sections (Scale bar = 50 mm). E-F. Microglia were quantified and
compared among the groups by counting the number of cells in the field. Five random fields at 40X fields were counted for each condition under a
digital axoplan microscope. Results were shown as the cells counted per 40X field. * p,0.05 compared with wt; * * p,0.01, Compared with EAE.
doi:10.1371/journal.pone.0012400.g009
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In this study we demonstrate that PTx icv prevents the
dissemination of disease into the spinal cord. PTx icv administered
on day 7 inhibits the migration of macrophage/microglia
mitigating further infiltration and evidence of inflammation and
demyelination distally. Our studies confirm evidence of microglial
infiltration in the brain early in the course of disease (day 7), in
both the EAE and EAE +PTX icv model. However, in the EAE
model the infiltration is limited in magnitude and location to the
subpial and subependymal regions of the brain, whereas in the
EAE +PTX icv model the microglial are prolific throughout the
brain parenchyma. It has been hypothesized that downstream
accumulation of macrophage/microglia stimulated by Wallerian
degeneration which begins rostrally and is responsible for the distal
vasculature mediated infiltration and ascending paralysis. Our
data suggests that arrest of microglia migration rostrally prevents
degeneration and spinal cord infiltration distally by retaining
microglia locally abrogating dissemination to the spinal cord.
Our study applied PTx icv to an in vivo model to determine the
effects of early icv administration of PTx on microglia migration,
BBB integrity, lymphocyte infiltration, and subsequent demyelin-
ation and dissemination of the disease. Our PTx+EAE model
reflects some key features of multiple sclerosis lesions and provides
a novel approach to study the mechanism responsible for the
localization of demyelinating lesion in the brain versus spinal cord.
It may also provide a model to investigate the variable nature of
lesions in diseases such as relapsing remitting MS and indicate why
the development of lesions in one region of the neuroaxis may
temporarily preclude the lesions elsewhere. Finally this model
encourages the investigation of the pleotropic effects of infectious
elements such as PTx in the pathogenesis of MS and other
autoimmune disease.
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